{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NK+cells",
    "query": {
      "intervention": "NK cells"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 417,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NK+cells&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T10:48:34.433Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00062868",
      "title": "LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Non Hodgkin Lymphoma",
        "Lymphoepithelioma",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "LMP1/2 CTLs (ALCI - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Group C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion Group C)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 74,
      "start_date": "2003-09",
      "completion_date": "2020-04",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062868"
    },
    {
      "nct_id": "NCT01142674",
      "title": "T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lymphoma, T-Cell, Peripheral"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Associazione Angela Serra per la ricerca sul cancro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1650,
      "start_date": "2006-09",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-07-08",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01142674"
    },
    {
      "nct_id": "NCT02452697",
      "title": "Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloid Malignancies",
        "Lymphoid Malignancies"
      ],
      "interventions": [
        {
          "name": "NK Cell enriched-DLI only",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NK-DLI + DUK-CPG-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cristina Gasparetto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2016-06-08",
      "completion_date": "2024-10",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452697"
    },
    {
      "nct_id": "NCT00323323",
      "title": "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "CHOP",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Plasma Samples",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-03",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323323"
    },
    {
      "nct_id": "NCT01309789",
      "title": "A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Large-Cell, Anaplastic",
        "Lymphoma, NK-cell",
        "Lymphoma, T-cell"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2011-02",
      "completion_date": "2017-02-28",
      "has_results": false,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01309789"
    },
    {
      "nct_id": "NCT02100891",
      "title": "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ewing Sarcoma",
        "Neuroblastoma",
        "Rhabdomyosarcoma",
        "Osteosarcoma",
        "CNS Tumors"
      ],
      "interventions": [
        {
          "name": "Allogeneic HCT",
          "type": "PROCEDURE"
        },
        {
          "name": "Donor NK Cell Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Monica Thakar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2013-03-20",
      "completion_date": "2020-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 2,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02100891"
    },
    {
      "nct_id": "NCT04673617",
      "title": "AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AB-101",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2021-03-29",
      "completion_date": "2025-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04673617"
    },
    {
      "nct_id": "NCT04395092",
      "title": "Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndromes (MDS)"
      ],
      "interventions": [
        {
          "name": "K-NK002",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Conditioning Regimen",
          "type": "PROCEDURE"
        },
        {
          "name": "HaploBMT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Kiadis Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-11-13",
      "completion_date": "2023-11",
      "has_results": false,
      "last_update_posted_date": "2021-06-22",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04395092"
    },
    {
      "nct_id": "NCT02301065",
      "title": "Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 35,
      "start_date": "2016-10-13",
      "completion_date": "2017-02-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301065"
    },
    {
      "nct_id": "NCT04881539",
      "title": "CBD, Immune Function, and Neural Health",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Cannabidiol (CBD)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Northern Colorado",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-05-15",
      "completion_date": "2022-03-18",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-09-03T10:48:34.433Z",
      "location_count": 1,
      "location_summary": "Greeley, Colorado",
      "locations": [
        {
          "city": "Greeley",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04881539"
    }
  ]
}